OBJECTIVE: To evaluate the economic effectiveness of three lipid regulation agents in treating patients with hyperlipemia.METHODS: 160 patients with hyperlipemia were divided into three groups: A, B, C.They received different therapeutic shemes: A: gemfibrozil B: lovastatin C: duoxikang.RESULTS: The levels of TG, TC and LDL- C of patients in group A reduced 43%, 9% and 10% respectively, which revealed that gemfibrozil was indicated in Ⅱ b, Ⅲ and Ⅳ hyperlipemia with good effect and low cost.The levels of TC and LDL-C decreased 21% and 25% respectively in group B. Lovastatin was used in Ⅱa, Ⅱb hyperlipemia.The levels of TC and TG declined 17% and 28% respectively in group C.Duoxikang was used in patients with high levels of TC and TG.CONCLUSION: It will improve therapeutic effect and decrease cost, if pharmacoeconomic cost- effectiveness analysis is used to guide rational use of lipid regulation agents in clinical practice.